AlphAIAlphAI — Financial news for AI agents
investing.com$ZBH

Stifel raises Zimmer Biomet stock price target on strong quarter

Stifel raised its price target for Zimmer Biomet (ZBH) to $125 from $110, citing strong Q3 2026 results. Revenue was $2.06B, beating estimates by $23M, with 8.6% growth and 69.5% gross margin. Hip products and S.E.T. segment drove outperformance. ZBH expects to launch Monogram robot in H1 2027. Stock is up 18% in six months, near 52-week high.

Original reporting
investing.com
Published Nov 4, 2026, 9:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ZBH
Bullish
high confidence
Mentioned
$ZBH
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ZBHBullishMed
01

Why it matters

The earnings beat and higher price target suggest a short‑term rally, but execution risk in knee sales and upcoming FDA clearance for the autonomous robot remain concerns.

02

Market read

Earnings beat and analyst upgrade provide a fresh catalyst for ZBH, likely driving short‑term buying interest.

03

What to watch

Potential regulatory delays for the autonomous robot launch and macro headwinds in China.

Relevance 7/10Novelty 8/10Timing: post-market today

Background

Zimmer Biomet reported Q3 2026 results, beating revenue and EPS expectations, and raised its full‑year outlook.

Company-level read

Ticker impact

$ZBHBullishHigh confidence
Context

Stifel raised its price target on Zimmer Biomet to $125 after the company reported Q3 2026 revenue of $2.06 B beating estimates and slightly higher EPS.

Expected impact

likely upward pressure as the market prices in the higher price target and earnings beat.

Evidence & confidence

The price target increase from $110 to $125 reflects a 13.6% upside, and the earnings beat signals stronger than expected performance.

Market effects

Sector

Positive earnings and target raise may lift other orthopedic device makers.

Regional

U.S. medical device sector sees modest boost.

Global

Limited to U.S. and global healthcare equipment investors.

Counterpoint

What could challenge this read

The knee segment missed estimates and China demand remains weak, which could temper upside.

Key entities

  • company
    Zimmer Biomet Holdings Inc.

    Medical device manufacturer reporting Q3 earnings.

  • analyst
    Stifel

    Raised price target to $125.

Read at source← All news

StoryZimmer Biomet reports Q3 2026 results and lifts full‑year guidance

Also covered by

5 outlets

Related articles

$ZBHMedAI 8/10

Zimmer Biomet (ZBH) Q3 2026 Earnings Call Transcript

Zimmer Biomet (ZBH) reported Q3 2026 net sales of $2.63B, up 3.7% in constant currency. Growth was driven by hips, S.E.T., and technology, while knees declined 2.6%. The company raised its 2026 guidance, expecting 3% to 3.5% constant currency sales growth and $8.50 to $8.60 adjusted EPS. Strategic priorities include sales force transition, robotics expansion, and diversification.

finance.yahoo.com
$ZBHHighAI 8/10

Zimmer raises sales forecast despite slower knee business

Zimmer Biomet reported Q3 sales of $2.06B, up 3.1% YoY, with knee sales down 3.1% but hip sales up 6%. The company raised its 2026 revenue growth forecast to 4.4-4.9%. CEO Ivan Tornos attributed knee sales decline to commercial execution and market competition, not a broader slowdown, according to the company. Analysts, however, suggest market-related weakness. Zimmer plans to file an FDA application for a new surgical robot, acquired via Monogram Technologies, expecting a 2027 launch.

finance.yahoo.com
$ZBHHighAI 9/10

Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy

Zimmer Biomet (ZBH) shares rose 15% after Q3 sales grew 3.7% in constant currency, with hips, sports medicine, and technology segments growing 7% or more. The company raised its 2026 guidance, citing progress in diversification. Knees, 37% of sales, declined 2.6%. Rival Stryker (SYK) and Smith & Nephew (SNN) also saw gains, despite Smith & Nephew cutting its outlook.

finance.yahoo.com
$ZBHHighAI 8/10

Zimmer Biomet Q3 Profit Falls, Lifts FY26 Outlook

Zimmer Biomet (ZBH) reported Q3 net earnings of $191.6M ($1.0 per share), down from $230.9M ($1.16 per share) a year earlier. Adjusted earnings were $362.8M ($1.90 per share), with net sales rising 3.1% to $2.06B. The company raised its FY26 adjusted EPS outlook to $8.50-$8.60 and revenue growth forecast to 4.4%-4.9%.

rttnews.com